Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation

NCT01729871 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.

NCT NCT01729871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01729871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation
Lead sponsor
Janssen Scientific Affairs, LLC
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
October 31, 2014
Enrollment
253 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation